Company: HURA
Filing Date: 2025-05-07
Form Type: 425
Source: 0000950170-25-065063
Chunk: 9

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-07
Form: 425
Chunk 9
---
 a period of 5 months plus COBRA premium reimbursement for the 6-month period following his termination. The Separation Agreement also provides that Mr. Yamashita vested as to 65,597 of his previously granted options, all of which will be exercisable through January 19, 2027. As a part of the Separation Agreement, Mr. Yamashita has agreed to a general release and waiver of claims against the Company upon the terms more particularly set forth in the Separation Agreement. The foregoing description of the Separation Agreement does not purport to be complete and is subject to, and qualified in its entirety by reference to, the full text of the Separation Agreement, which is attached as Exhibit 10.1 hereto and incorporated herein by reference. Item 9.01 Financial Statements and Exhibits. (d) Exhibits

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

| Date: | May 6, 2025 | By: | TUHURA BIOSCIENCES, INC.       
 /s/ Dan Dearborn               |
|:------|:------------|:----|:-------------------------------|
|       |             |     | Name: Dan Dearborn             
 Title: Chief Financial Officer |

<div align='center'>Exhibit 10.1

SEPARATION AGREEMENT</div>

THIS SEPARATION AGREEMENT(this “Agreement”) is dated as of May 5, 2025, by and between DENNIS YAMASHITA, an individual whose address is [*] (“Employee”), and TuHURA Biosciences, Inc., a Nevada corporation, whose principal place of business is located at 10500 University Center Drive, Suite 110, Tampa, Florida 33612 (the “Company”). The Company and Employee are individually referred to as a “Party” and are collectively referred to in this Agreement as the “Parties.”

<div align='center'>RECITALS</div>

Employee is a party to an Employment Agreement, dated December 19, 2023, between Employee and TuHURA Biosciences, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“TuHURA Delaware”), pursuant to which Employee was employed as the Chief Scientific Officer of TuHURA Delaware (the “Employment Agreement”).

Effective October 18, 2024, the Employment Agreement was assigned